CTX-130
CRISPR Therapeutics AG
[]
(crispr therapeutics presents positive results from its phase 1 cobalt -lym trial of ctx130 in relapsed or refractory t cell malignancies at the 2022 european hematology association (eha) congress | dna rna an ...) has been published on - 